Blossomhill Therapeutics, Inc. · NASDAQ:BLSM
Liptak Vincent Paul bought 4,700 Blossomhill Therapeutics, Inc. shares (Form 4)
Traded Aug 7 to Aug 10, 2026 · Filed Aug 10, 2026
From Aug 7 to Aug 10, 2026, Liptak Vincent Paul (General Counsel) bought 4,700 Blossomhill Therapeutics, Inc. shares at an average US$15.89 for US$74,700, leaving 22,687 shares. Filed Aug 10, 2026 (Form 4).
- Bought
- 4,700 shares
- Price
- US$15.89 average (US$15.80 to US$16.00)
- Value
- US$74,700
- Holding after
- 22,687 shares (held indirectly)
- Trading plan
- No
- Role
- General Counsel
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Common Stock | Buy | 2,500 | US$15.80 | 109,212 | Direct |
| Aug 10, 2026 | Common Stock | Buy | 2,200 | US$16.00 | 111,412 | Direct |
| Aug 10, 2026 | Common Stock | Conversion | 22,687 | 22,687 | Indirect |
Source
Related
- Blossomhill Therapeutics, Inc.
- Liptak Vincent Paul
- Blossomhill Therapeutics, Inc. shareholders
- Schedule 13D · Orbimed Advisors LLC · Aug 18, 2026
- Schedule 13G · Vivo Innovation Fund II Holdings, L.P. · Aug 17, 2026
- Schedule 13G · Perceptive Advisors LLC · Aug 14, 2026
- Schedule 13D · Chen Bihua · Aug 13, 2026
- Form 4 · Gordon Carl L · Aug 12, 2026